Lipophilic Prodrugs of FR900098 Are Antimicrobial against Francisella novicida In Vivo and In Vitro and Show GlpT Independent Efficacy
Open Access
- 15 October 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e38167
Abstract
Bacteria, plants, and algae produce isoprenoids through the methylerythritol phosphate (MEP) pathway, an attractive pathway for antimicrobial drug development as it is present in prokaryotes and some lower eukaryotes but absent from human cells. The first committed step of the MEP pathway is catalyzed by 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR/MEP synthase). MEP pathway genes have been identified in many biothreat agents, including Francisella, Brucella, Bacillus, Burkholderia, and Yersinia. The importance of the MEP pathway to Francisella is demonstrated by the fact that MEP pathway mutations are lethal. We have previously established that fosmidomycin inhibits purified MEP synthase (DXR) from F. tularensis LVS. FR900098, the acetyl derivative of fosmidomycin, was found to inhibit the activity of purified DXR from F. tularensis LVS (IC50 = 230 nM). Fosmidomycin and FR900098 are effective against purified DXR from Mycobacterium tuberculosis as well, but have no effect on whole cells because the compounds are too polar to penetrate the thick cell wall. Fosmidomycin requires the GlpT transporter to enter cells, and this is absent in some pathogens, including M. tuberculosis. In this study, we have identified the GlpT homologs in F. novicida and tested transposon insertion mutants of glpT. We showed that FR900098 also requires GlpT for full activity against F. novicida. Thus, we synthesized several FR900098 prodrugs that have lipophilic groups to facilitate their passage through the bacterial cell wall and bypass the requirement for the GlpT transporter. One compound, that we termed “compound 1,” was found to have GlpT-independent antimicrobial activity. We tested the ability of this best performing prodrug to inhibit F. novicida intracellular infection of eukaryotic cell lines and the caterpillar Galleria mellonella as an in vivo infection model. As a lipophilic GlpT-independent DXR inhibitor, compound 1 has the potential to be a broad-spectrum antibiotic, and should be effective against most MEP-dependent organisms.Keywords
This publication has 48 references indexed in Scilit:
- Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogsBioorganic & Medicinal Chemistry Letters, 2011
- A Second Target of the Antimalarial and Antibacterial Agent Fosmidomycin Revealed by Cellular Metabolic ProfilingBiochemistry, 2011
- Challenges of Antibacterial DiscoveryClinical Microbiology Reviews, 2011
- A new family of enzymes catalyzing the first committed step of the methylerythritol 4-phosphate (MEP) pathway for isoprenoid biosynthesis in bacteriaProceedings of the National Academy of Sciences, 2010
- Working toward the Future: Insights intoFrancisella tularensisPathogenesis and Vaccine DevelopmentMicrobiology and Molecular Biology Reviews, 2009
- Antibiotic-Resistant Bugs in the 21st Century — A Clinical Super-ChallengeNew England Journal of Medicine, 2009
- Galleria mellonella as a model host to study infection by the Francisella tularensis live vaccine strainMicrobes and Infection, 2007
- In vivo negative selection screen identifies genes required for Francisella virulenceProceedings of the National Academy of Sciences, 2007
- A comprehensive transposon mutant library of Francisella novicida , a bioweapon surrogateProceedings of the National Academy of Sciences, 2007
- Sampling the Antibiotic ResistomeScience, 2006